Literature DB >> 3227815

Exogenous interleukin regulates growth of C6 tumors in vivo.

M J Politis1, J K Lindsay.   

Abstract

Elvax pellets containing interleukin 1 (IL-1) or 2 (IL-2) were assessed for their ability to alter the growth of transplanted C6 cells in rat. C6 cells were injected into the left caudate of Sprague Dawley rats. At the time of tumor cell injection, or 9 days later, Elvax pellets containing either 50 or 200 units of interleukin were inserted into the dorsal aspect of the caudate. Animals were killed 16 days later and the volume of tumors determined. Results showed that introduction of low-dose IL-2 pellets at time of C6 cell injection virtually prevented establishment of tumors, whereas low-dose IL-1 pellet insertion resulted in nearly a threefold increase in tumor size relative to control preparations. Insertion of high-dose IL-2 pellets 9 days after C6 cell injection decreased tumor growth relative to controls by nearly twofold, low-dose pellets having no effect. These effects appear to be mediated by alterations in host brains, vs interleukin-moderating effects on growth of C6 cells themselves, since (a) no effect of IL-2 on C6 cell growth in vitro could be demonstrated and IL-1 appeared to enhance their proliferation in culture, and (b) IL-1 pellets diminished and IL-2 pellets enhanced infiltration of inflammatory cells into brain when implanted into brain after a "stab" wound.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3227815     DOI: 10.1007/bf00687429

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

Review 1.  Interleukins.

Authors:  K Bendtzen
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1985       Impact factor: 2.268

2.  An in vivo assay of neurotropic activity.

Authors:  M J Politis; P S Spencer
Journal:  Brain Res       Date:  1983-11-14       Impact factor: 3.252

3.  In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.

Authors:  S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal:  J Neurosurg       Date:  1986-01       Impact factor: 5.115

4.  Human mononuclear cell factors mediate cartilage matrix degradation through chondrocyte activation.

Authors:  H E Jasin; J T Dingle
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

5.  Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

Authors:  S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

6.  Interleukin-1 stimulation of astroglial proliferation after brain injury.

Authors:  D Giulian; L B Lachman
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

7.  A new glioma model in rat: the C6 spheroid implantation technique permeability and vascular characterization.

Authors:  C L Farrell; P A Stewart; R F Del Maestro
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

8.  Astrocytes of the brain synthesize interleukin 3-like factors.

Authors:  K Frei; S Bodmer; C Schwerdel; A Fontana
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

9.  Interleukin 1 of the central nervous system is produced by ameboid microglia.

Authors:  D Giulian; T J Baker; L C Shih; L B Lachman
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

10.  Interleukin 1 stimulation of collagenase production by cultured fibroblasts.

Authors:  A E Postlethwaite; L B Lachman; C L Mainardi; A H Kang
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.